[go: up one dir, main page]

WO2005076007A3 - Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) - Google Patents

Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) Download PDF

Info

Publication number
WO2005076007A3
WO2005076007A3 PCT/EP2005/000632 EP2005000632W WO2005076007A3 WO 2005076007 A3 WO2005076007 A3 WO 2005076007A3 EP 2005000632 W EP2005000632 W EP 2005000632W WO 2005076007 A3 WO2005076007 A3 WO 2005076007A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
therapeutics
diagnostics
protein
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/000632
Other languages
English (en)
Other versions
WO2005076007A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2005076007A2 publication Critical patent/WO2005076007A2/fr
Publication of WO2005076007A3 publication Critical patent/WO2005076007A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne le P2Y12 humain associé aux maladies cardio-vasculaires, aux maladies endocrinologiques, aux maladies métaboliques, aux maladies gastroentérologiques, au cancer, aux inflammations, aux maladies hématologiques, aux maladies respiratoires, aux maladies neurologiques et aux maladies urologiques. L'invention concerne également des dosages permettant d'identifier des composés utilisés pour traiter ou prévenir les maladies cardio-vasculaires, les maladies endocrinologiques, les maladies métaboliques, les maladies gastroentérologiques, le cancer, les inflammations, les maladies hématologiques, les maladies respiratoires, les maladies neurologiques et les maladies urologiques. L'invention concerne enfin des composés qui se lient à P2Y12 et/ou activent or inhibent son activité ainsi que des compositions pharmaceutiques comprenant ces composés.
PCT/EP2005/000632 2004-02-03 2005-01-22 Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) Ceased WO2005076007A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002290.7 2004-02-03
EP04002290 2004-02-03

Publications (2)

Publication Number Publication Date
WO2005076007A2 WO2005076007A2 (fr) 2005-08-18
WO2005076007A3 true WO2005076007A3 (fr) 2006-01-26

Family

ID=34833561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000632 Ceased WO2005076007A2 (fr) 2004-02-03 2005-01-22 Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)

Country Status (1)

Country Link
WO (1) WO2005076007A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299097B2 (en) 2008-09-12 2012-10-30 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory disorders
AU2015227476B2 (en) * 2010-10-18 2017-03-23 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
HRP20171587T1 (hr) 2010-10-18 2017-12-01 Cerenis Therapeutics Holding Sa Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola
WO2013033178A1 (fr) * 2011-08-30 2013-03-07 University Of Utah Research Foundation Procédés et compositions pour traiter le diabète insipide néphrogénique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046497A1 (en) * 2000-04-21 2001-11-29 Zhang Fang Liang G-protein coupled receptor and methods
US20030124626A1 (en) * 2000-11-01 2003-07-03 Jun Takasaki Method of screening antiplatelet
WO2004065576A2 (fr) * 2003-01-15 2004-08-05 Millennium Pharmaceuticals, Inc. Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603,

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046497A1 (en) * 2000-04-21 2001-11-29 Zhang Fang Liang G-protein coupled receptor and methods
US20030124626A1 (en) * 2000-11-01 2003-07-03 Jun Takasaki Method of screening antiplatelet
WO2004065576A2 (fr) * 2003-01-15 2004-08-05 Millennium Pharmaceuticals, Inc. Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603,

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOLLOPETER GUNTHER ET AL: "Identification of the platelet ADP receptor targeted by antithrombotic drugs", NATURE (LONDON), vol. 409, no. 6817, 11 January 2001 (2001-01-11), pages 202 - 207, XP002333079, ISSN: 0028-0836 *
KUNAPULI SATYA P ET AL: "ADP receptors-targets for developing antithrombotic agents.", CURRENT PHARMACEUTICAL DESIGN, vol. 9, no. 28, 2003, pages 2303 - 2316, XP008049019, ISSN: 1381-6128 *
TAKASAKI JUN ET AL: "Molecular cloning of the platelet P2TAC ADP receptor: Pharmacological comparison with another ADP receptor, the P2Y1 receptor", MOLECULAR PHARMACOLOGY, vol. 60, no. 3, September 2001 (2001-09-01), pages 432 - 439, XP002333080, ISSN: 0026-895X *

Also Published As

Publication number Publication date
WO2005076007A2 (fr) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2006005469A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2006005470A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge)
WO2005101001A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2005113788A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6)
WO2005119263A3 (fr) Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2005114210A8 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3)
WO2005040791A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr)
WO2005114209A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 2 specifique du recepteur couple a une proteine g (grk2)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2006040047A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase citron agissant sur rho/rac
WO2005101011A3 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2005108998A3 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2005101006A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur beta du retinoide x (rxrb)
WO2005075990A3 (fr) Diagnostics et therapeutiques pour maladies associees au recepteur nucleaire humain nr4a2 (nr4a2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase